Request Demo
Fierce Biotech's Quarterly IPO and M&A Roundup: Q2'24
IPOAcquisition
A standout deal of the second quarter M&A activity was Novartis’ acquisition of Mariana Oncology, a no-brainer deal from the leading radiopharma company.
Biopharma deal activity plummeted down to Earth in the Novartisuarter, with justMariana OncologyA transactions and IPOs studding the mostly dark skies.
Biopharmaquarter follows an exciting first one in which pharma finally spent some of the trillions in cash hanging around for such transactions.
Standouts of the second quarter M&A activity were Novartis’ acquisition of Mariana Oncology, a no-brainer deal from the leading radiopharma company. Novartis is shelling out $1 billion upfront for Mariana to tuck in some additional radioligand assets to its roster that includes Pluvicto and Lutathera. The Swiss pharma specifically wanted to get its hands on Mariana due to its focus on the radioactive metallic element actinium, which would provide differentiation.
The deal followed a number of Big Pharma forays inNovartispharma in previouMariana Oncologyuding biotech buyouts executed by Eli Lilly and Bristol MyNovartisbb.PluvictoLutathera
Another big ticket in the second quarter was Biogen’s $1.15 billion acquisition of Human Immunology Biosciences (HI-Bio). WitEliELillyis ViBristol Myers Squibbiversify Biogen’s future, HI-Bio brings an anti-CD38 monoclonal antibody that is soon to enter phase 3 trials in multiple rare immune-mediated indications.
See last quarter's report here: Fierce BiotecBiogenarterly IPO and M&A Roundup: Q1'Human Immunology BiosciencesHI-BioBiogenHI-Bioanti-CD38 monoclonal antibody
Merck & Co. signed the largest deal of the quarter, buying ophthalmology-focused Eyebiotech for $3 billion. The deal features $1.3 billion in cash upfront and $1.7 billion in potential milestones.
Merck & Co.lic.flourish.studio/visualisation/18515377/Eyebiotech
Over on the IPO markets, the second quarter saw a total of four biotechs prepare to jump to the Nasdaq. Actuate Therapeutics unveiled plans for a $50 million IPO, while Rapport Therapeutics closed its own offering to the tune of $136 million. The third was immune-mediated disease biotech Alumis, which downsized its plans for a $274 million IPO in the final days of June to eventually comprise $250 million spread across both an IPO and private placement.
On the same day Alumis went public, NK cell therapy biotech Artiva Biotherapeutics also revealed that itActuate Therapeutics although details remain limited at this stagRapport Therapeuticsimmune-mediated disease
And then there wAlumisix Pharmaceuticals, which yanked its oArtiva Biotherapeuticsst minute. The radiopharma-focused biotech, which has been listed on the Australian Securities Exchange since 2017, had been due to join the Nasdaq on June 14. The IPO had been expected to draw $183 million—or $211 million if underwriters took up their full option.
Instead, the companTelix Pharmaceuticalsting: “Given the proposed Nasdaq listing was not predicated on the need to raise capital, Telix’s management and board of directors have decided not to move forward with the transaction at the terms provided under current market conditions.”
https://public.flourish.studio/visualisation/18515356/Telix
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.